@article{dbdcc3119077494c996941f294581b3d,
title = "Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis",
abstract = "Natalizumab is a recombinant humanized monoclonal antibody that decreases T-cell migration into the central nervous system (CNS) through α4 integrin:adhesion-molecule inhibition, thereby increasing the risk for opportunistic CNS infection. Herein, we report a case of infusion-associated aseptic meningitis in a patient receiving natalizumab.",
keywords = "MRI, Multiple sclerosis, disease-modifying therapies, natalizumab",
author = "Foley, {Robert W.} and Tagg, {Nathan T.} and Schindler, {Matthew K.} and Fenton, {Kaylan M.} and Reich, {Daniel S.} and Irene Cortese and Mowry, {Ellen M.}",
note = "Funding Information: Drug-induced aseptic meningitis is an uncommon The author(s) disclosed receipt of the following financial occurrence10 and has not previously been reported support for the research, authorship, and/or publication with natalizumab. That being said, it may be possible of this article: This research was partially supported by that more mild cases thereof occur with some fre-the Intramural Research Program of the National quency, and it would be ideal to systematically evalu-Institute of Neurological Disorders and Stroke (NINDS). ate cohorts of people receiving natalizumab to assess headache frequency and to characterize the types and timing of headaches experienced by patients. The mechanism by which drug-induced aseptic meningitis is associated with natalizumab and other monoclonal antibodies is unclear; others have suggested, in delayed-onset cases such as ours, a serum sickness- like illness may be explanatory.11 Regardless, natali- zumab-related aseptic meningitis should be included in the differential diagnosis of symptoms consistent with meningitis in patients treated with natalizumab and other biological agents likely to be increasingly used by people with MS, although this diagnosis should be made only after a full infectious workup is negative. Whether medications such as non-steroidal agents, anti-histamines, or corticosteroids could help Funding Information: The author (s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Reich{\textquoteright}s research is supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke. He has also received research funding from the Myelin Repair Foundation and Vertex Pharmaceuticals. Dr Mowry has received research funding from Biogen and free medication for a trial from Teva Neuroscience. She is site PI of trials from Biogen and Sun Pharma. She has received royalties from UpToDate for editorial duties. Mr Foley reports no disclosures. Dr Schindler reports no disclosures. Ms Fenton reports no disclosures. Publisher Copyright: {\textcopyright} 2017, {\textcopyright} The Author(s), 2017.",
year = "2017",
month = sep,
day = "1",
doi = "10.1177/1352458517702533",
language = "English (US)",
volume = "23",
pages = "1424--1427",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "10",
}